TY - JOUR
T1 - Eosinophilic Solid and Cystic Renal Cell Carcinoma (ESC RCC)
T2 - Further Morphologic and Molecular Characterization of ESC RCC as a Distinct Entity
AU - Trpkov, Kiril
AU - Abou-Ouf, Hatem
AU - Hes, Ondřej
AU - Lopez, Jose I.
AU - Nesi, Gabriella
AU - Comperat, Eva
AU - Sibony, Mathilde
AU - Osunkoya, Adeboye O.
AU - Zhou, Ming
AU - Gokden, Neriman
AU - Leroy, Xavier
AU - Berney, Daniel M.
AU - Werneck Cunha, Isabela
AU - Musto, Maria L.
AU - Athanazio, Daniel A.
AU - Yilmaz, Asli
AU - Donnelly, Bryan
AU - Hyndman, Eric
AU - Gill, Anthony J.
AU - McKenney, Jesse K.
AU - Bismar, Tarek A.
N1 - Funding Information:
Conflicts of Interest and Source of Funding: Supported in part by Calgary Laboratory Services, Southern Alberta Urology Institute, and Charles University Research Fund (project number P36), by the project CZ.1.05/2.1.00/03.0076 from the European Regional Devel-opment Fund and by the project FN 00669806. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
PY - 2017
Y1 - 2017
N2 - Eosinophilic solid and cystic renal cell carcinoma (ESC RCC) has been recently described as a unique and indolent renal neoplasm, found in female patients with and without tuberous sclerosis complex. Although ESC RCC has a distinct morphology and frequent CK20 reactivity, its molecular karyotype has been previously studied only in few cases. We identified 19 ESC RCC from multiple institutions; all patients were female individuals without clinical features of tuberous sclerosis complex. Molecular karyotyping was performed in 13 cases (12 with informative result). The median age was 55 years (range: 32 to 79 y). The tumors were yellow-gray with a median size of 31 mm (range: 12 to 135 mm) and showed solid and cystic gross appearance. All tumors demonstrated typical microscopic features with solid areas admixed with variably sized macrocysts and microcysts. The cells showed eosinophilic cytoplasm with granular cytoplasmic stippling and round-to-oval nuclei. CK20 was positive in 14/19 (74%) cases. Stage pT1 was found in 17/19 (89%) patients (pT1a in 12, pT1b in 5); 1 patient each had pT2a and pT3a. A total of 15/16 patients with available follow-up were alive and without evidence of disease progression, after 1 to 169 months (median: 44 mo; mean: 49.6 mo); 3 died of other causes. The most common copy number gains were 16p13.3-16q23.1 (33% to 67%), 7p21.2-7q36.2 (42% to 50%), 13q14.2 (33%), and 19p12 (33%). The most common copy number losses included Xp11.21 (42%) and 22q11.23 (33%). Loss of heterozygosity was most frequently found at 16p11.2-11.1 (75%), Xq11.1-13.1 (75%), Xq13.1-21.1 (33%), 11p11.2-11.11 (33%), 9q21.1-22.2 (33%), and 9q33.1 (33%). ESC RCC demonstrates common molecular karyotype alterations, which further support its distinct nature.
AB - Eosinophilic solid and cystic renal cell carcinoma (ESC RCC) has been recently described as a unique and indolent renal neoplasm, found in female patients with and without tuberous sclerosis complex. Although ESC RCC has a distinct morphology and frequent CK20 reactivity, its molecular karyotype has been previously studied only in few cases. We identified 19 ESC RCC from multiple institutions; all patients were female individuals without clinical features of tuberous sclerosis complex. Molecular karyotyping was performed in 13 cases (12 with informative result). The median age was 55 years (range: 32 to 79 y). The tumors were yellow-gray with a median size of 31 mm (range: 12 to 135 mm) and showed solid and cystic gross appearance. All tumors demonstrated typical microscopic features with solid areas admixed with variably sized macrocysts and microcysts. The cells showed eosinophilic cytoplasm with granular cytoplasmic stippling and round-to-oval nuclei. CK20 was positive in 14/19 (74%) cases. Stage pT1 was found in 17/19 (89%) patients (pT1a in 12, pT1b in 5); 1 patient each had pT2a and pT3a. A total of 15/16 patients with available follow-up were alive and without evidence of disease progression, after 1 to 169 months (median: 44 mo; mean: 49.6 mo); 3 died of other causes. The most common copy number gains were 16p13.3-16q23.1 (33% to 67%), 7p21.2-7q36.2 (42% to 50%), 13q14.2 (33%), and 19p12 (33%). The most common copy number losses included Xp11.21 (42%) and 22q11.23 (33%). Loss of heterozygosity was most frequently found at 16p11.2-11.1 (75%), Xq11.1-13.1 (75%), Xq13.1-21.1 (33%), 11p11.2-11.11 (33%), 9q21.1-22.2 (33%), and 9q33.1 (33%). ESC RCC demonstrates common molecular karyotype alterations, which further support its distinct nature.
KW - CK20
KW - eosinophilic tumor
KW - renal cell carcinoma
KW - tuberous sclerosis
KW - unclassified oncocytic tumor
KW - unclassified renal cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85030620083&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030620083&partnerID=8YFLogxK
U2 - 10.1097/PAS.0000000000000838
DO - 10.1097/PAS.0000000000000838
M3 - Article
C2 - 28786877
AN - SCOPUS:85030620083
SN - 0147-5185
VL - 41
SP - 1299
EP - 1308
JO - American Journal of Surgical Pathology
JF - American Journal of Surgical Pathology
IS - 10
ER -